Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.

Paola GuglielmelliAlessio MazzoniLaura MaggiSeble Tekle KirosLorenzo ZammarchiSofia PilerciArianna RoccaMichele SpinicciMiriam BorellaAlessandro BartoloniGian Maria RossoliniFrancesco AnnunziatoAlessandro Maria Maria Vannucchi

Published in: American journal of hematology (2021)

Keyphrases

sars cov
respiratory syndrome coronavirus
low grade
coronavirus disease